PLK1 (P53350) variants and mutations
PLK1 (also known as P53350) is a human protein-coding gene encoding a serine/threonine-protein kinase protein. It coordinates centrosome maturation, chromosome segregation, spindle function, and cytokinesis during mitosis. Many tumors overexpress PLK1 and depend on its activity for rapid proliferation, making it a prominent anticancer drug target. This analysis covers 776 PLK1 variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes neurodegenerative disease, Alzheimer disease, and Parkinson disease. Example PLK1 variants include S2G, S2C, and S2N.
Variant analysis overview
- Gene: PLK1
- Protein: P53350
- UniProt accession: P53350
- Organism: Homo sapiens
- Variants analyzed: 776
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 551 unspecified-consequence records; 110 missense variants; 98 synonymous variants; 10 frameshift variants; 3 in-frame deletions; 1 stop-gained variants; 1 in-frame insertions; 2 substitution
- Prediction scores: 613 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neurodegenerative disease, Alzheimer disease, Parkinson disease, lysosomal storage disease, multiple sclerosis, microcephaly, Intellectual disability, epilepsy, genetic developmental and epileptic encephalopathy, developmental and epileptic encephalopathy, acute myeloid leukemia by FAB classification, autoimmune disorder of central nervous system.
Protein structure and variant hotspots
- Protein features: 3 domains; 5 binding sites; 11 post-translational modification sites.
- Structural context: 453 variants have structural context.
- PTM context: 23 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PLK1 variants
Examples include S2G, S2C, S2N, S2I, S2S, A3T, A3S, A3D. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- S2G (p.Ser2Gly), gnomAD 16-23678936-A-G, REVEL 0.22, CADD 23.30
- S2C (p.Ser2Cys), gnomAD 16-23678936-A-T, REVEL 0.18, CADD 23.60
- S2N (p.Ser2Asn), gnomAD 16-23678937-G-A, REVEL 0.11, CADD 19.30
- S2I (p.Ser2Ile), gnomAD 16-23678937-G-T, REVEL 0.13, CADD 20.90
- S2S (p.Ser2Ser), rs1407081351, gnomAD 16-23678938-T-C, CADD 11.30
- A3T (p.Ala3Thr), gnomAD 16-23678939-G-A, REVEL 0.18, CADD 20.10
- A3S (p.Ala3Ser), gnomAD 16-23678939-G-T, REVEL 0.19, CADD 18.60
- A3D (p.Ala3Asp), gnomAD 16-23678940-C-A, REVEL 0.23, CADD 22.10
- A3A (p.Ala3Ala), rs1400802092, gnomAD 16-23678941-T-G, CADD 8.59
- A4S (p.Ala4Ser), rs759656440, ClinGen CA7964124, ClinVar RCV004150718, ExAC rs759656440, REVEL 0.11, CADD 19.80, Uncertain significance, not specified
- A4V (p.Ala4Val), NCI-TCGA TCGA novel, REVEL 0.07, CADD 20.50, Variant assessed as somatic; moderate impact.
- A4T (p.Ala4Thr), gnomAD 16-23678942-G-A, REVEL 0.10, CADD 22.90
- A4E (p.Ala4Glu), gnomAD 16-23678943-C-A, REVEL 0.06, CADD 16.10
- A4G (p.Ala4Gly), gnomAD 16-23678943-C-G, REVEL 0.06, CADD 16.20
- A4A (p.Ala4Ala), gnomAD 16-23678944-A-G, CADD 10.40
- V5M (p.Val5Met), gnomAD rs1290386708, REVEL 0.10, CADD 17.80
- V5L (p.Val5Leu), gnomAD 16-23678945-G-T, REVEL 0.15, CADD 13.30
- V5V (p.Val5Val), rs780298441, gnomAD 16-23678947-G-C, CADD 5.91
- T6A (p.Thr6Ala), gnomAD rs1423596323, REVEL 0.17, CADD 6.74
- T6S (p.Thr6Ser), gnomAD 16-23678949-C-G, REVEL 0.09, CADD 12.80
- T6I (p.Thr6Ile), gnomAD 16-23678949-C-T, REVEL 0.06, CADD 17.80
- T6N (p.Thr6Asn), gnomAD 16-23678949-C-A, REVEL 0.11, CADD 16.60
- T6T (p.Thr6Thr), gnomAD 16-23678950-T-G, CADD 7.55
- A7S (p.Ala7Ser), TOPMed rs1021134870, gnomAD rs1021134870, REVEL 0.09, CADD 15.30
- A7T (p.Ala7Thr), gnomAD 16-23678951-G-A, REVEL 0.10, CADD 17.20
- A7V (p.Ala7Val), gnomAD 16-23678952-C-T, REVEL 0.13, CADD 22.20
- A7E (p.Ala7Glu), gnomAD 16-23678952-C-A, REVEL 0.17, CADD 21.60
- A7A (p.Ala7Ala), rs767993455, gnomAD 16-23678953-A-G, CADD 12.70
- G8E (p.Gly8Glu), TOPMed rs1245346767, REVEL 0.19, CADD 23.20
- G8W (p.Gly8Trp), gnomAD 16-23678954-G-T, REVEL 0.32, CADD 24.90
- G8R (p.Gly8Arg), gnomAD 16-23678954-G-A, REVEL 0.18, CADD 24.00
- G8V (p.Gly8Val), gnomAD 16-23678955-G-T, REVEL 0.27, CADD 23.20
- G8G (p.Gly8Gly), rs1350839409, gnomAD 16-23678956-G-T, CADD 13.00
- K9E (p.Lys9Glu), gnomAD rs1438981347, REVEL 0.32, CADD 23.50
- K9R (p.Lys9Arg), gnomAD 16-23678958-A-G, REVEL 0.22, CADD 22.80
- K9N (p.Lys9Asn), gnomAD 16-23678959-G-T, REVEL 0.14, CADD 22.90
- L10M (p.Leu10Met), gnomAD rs1278321103, REVEL 0.16, CADD 21.30
- L10L (p.Leu10Leu), rs1278321103, gnomAD 16-23678960-C-T, CADD 14.40
- L10P (p.Leu10Pro), gnomAD 16-23678961-T-C, REVEL 0.28, CADD 24.00
- A11T (p.Ala11Thr), gnomAD 16-23678963-G-A, REVEL 0.20, CADD 23.50
- A11E (p.Ala11Glu), gnomAD 16-23678964-C-A, REVEL 0.24, CADD 23.20
- A11V (p.Ala11Val), gnomAD 16-23678964-C-T, REVEL 0.20, CADD 22.80
- A11A (p.Ala11Ala), gnomAD 16-23678965-A-G, CADD 13.80
- R12L (p.Arg12Leu), rs1959276494, UniProt VAR 041018, gnomAD rs1959276494, REVEL 0.30, CADD 23.30, Uncertain significance, in a lung squamous cell carcinoma sample
- R12W (p.Arg12Trp), 1000Genomes rs571545759, ExAC rs571545759, TOPMed rs571545759, gnomAD rs571545759, REVEL 0.32, CADD 23.90
- R12R (p.Arg12Arg), gnomAD 16-23678966-C-A, CADD 14.70
- R12P (p.Arg12Pro), gnomAD 16-23678967-G-C, REVEL 0.39, CADD 24.80
- R12Q (p.Arg12Gln), gnomAD 16-23678967-G-A, REVEL 0.19, CADD 23.40
- A13T (p.Ala13Thr), gnomAD 16-23678969-G-A, REVEL 0.17, CADD 22.60
- A13E (p.Ala13Glu), gnomAD 16-23678970-C-A, REVEL 0.23, CADD 21.60
- A13V (p.Ala13Val), gnomAD 16-23678970-C-T, REVEL 0.16, CADD 21.80
- A13A (p.Ala13Ala), rs1959276691, gnomAD 16-23678971-A-T, CADD 14.10
- P14A (p.Pro14Ala), ExAC rs764367827, TOPMed rs764367827, gnomAD rs764367827, REVEL 0.17, CADD 19.80
- P14Q (p.Pro14Gln), gnomAD rs1959276853, REVEL 0.23, CADD 20.80
- P14L (p.Pro14Leu), gnomAD 16-23678973-C-T, REVEL 0.22, CADD 23.00
- P14P (p.Pro14Pro), gnomAD 16-23678974-G-T, CADD 6.73
- A15G (p.Ala15Gly), TOPMed rs1222018262, gnomAD rs1222018262, REVEL 0.14, CADD 21.30
- A15T (p.Ala15Thr), ExAC rs753468980, TOPMed rs753468980, gnomAD rs753468980, REVEL 0.14, CADD 24.20
- A15V (p.Ala15Val), TOPMed rs1222018262, gnomAD rs1222018262
- A15D (p.Ala15Asp), gnomAD 16-23678976-C-A, REVEL 0.19, CADD 21.80
- A15A (p.Ala15Ala), gnomAD 16-23678977-C-T, CADD 12.90
- D16Y (p.Asp16Tyr), Ensembl rs1959277217, REVEL 0.26, CADD 24.00
- D16N (p.Asp16Asn), gnomAD 16-23678978-G-A, REVEL 0.15, CADD 23.90
- D16G (p.Asp16Gly), gnomAD 16-23678979-A-G, REVEL 0.22, CADD 23.70
- P17H (p.Pro17His), NCI-TCGA TCGA novel, REVEL 0.07, CADD 18.20, Variant assessed as somatic; moderate impact.
- P17S (p.Pro17Ser), gnomAD rs1290770914, Uncertain significance, not specified
- P17P (p.Pro17Pro), gnomAD 16-23678983-T-C, CADD 6.61
- G18V (p.Gly18Val), gnomAD 16-23678985-G-T, REVEL 0.20, CADD 23.80
- G18G (p.Gly18Gly), rs11558151, gnomAD 16-23678986-G-A, CADD 11.30
- K19E (p.Lys19Glu), gnomAD rs1453123013, REVEL 0.15, CADD 22.60
- K19R (p.Lys19Arg), TOPMed rs966462064, gnomAD rs966462064, REVEL 0.11, CADD 21.50
- p.Lys19 Gly24del, gnomAD 16-23678986-GAAAG, CADD 21.20
- A20G (p.Ala20Gly), gnomAD rs1232261739, REVEL 0.11, CADD 14.80
- A20P (p.Ala20Pro), gnomAD 16-23678983-TG-T, CADD 28.00
- A20T (p.Ala20Thr), gnomAD 16-23678990-G-A, REVEL 0.07, CADD 19.90
- A20S (p.Ala20Ser), gnomAD 16-23678990-G-T, REVEL 0.05, CADD 18.80
- A20V (p.Ala20Val), gnomAD 16-23678991-C-T, REVEL 0.06, CADD 18.00
- A20D (p.Ala20Asp), gnomAD 16-23678991-C-A, REVEL 0.07, CADD 18.10
- A20A (p.Ala20Ala), rs756843600, gnomAD 16-23678992-C-T, CADD 9.09
- G21R (p.Gly21Arg), TOPMed rs1959277645, REVEL 0.23, CADD 23.60
- G21V (p.Gly21Val), rs765005937, ClinGen CA7964131, ClinVar RCV004173620, ExAC rs765005937, REVEL 0.23, CADD 23.50, Uncertain significance, not specified
- G21W (p.Gly21Trp), gnomAD 16-23678993-G-T, REVEL 0.36, CADD 26.70
- V22I (p.Val22Ile), gnomAD rs1382853622, REVEL 0.17, CADD 15.80
- V22F (p.Val22Phe), gnomAD 16-23678996-G-T, REVEL 0.18, CADD 17.10
- V22A (p.Val22Ala), gnomAD 16-23678997-T-C, REVEL 0.20, CADD 0.00
- V22V (p.Val22Val), rs1959277949, gnomAD 16-23678998-C-T, CADD 6.48
- P23T (p.Pro23Thr), gnomAD 16-23678999-C-A, REVEL 0.06, CADD 16.50
- P23P (p.Pro23Pro), gnomAD 16-23679001-C-A, CADD 1.58
- G24R (p.Gly24Arg), NCI-TCGA Cosmic COSV1002, REVEL 0.26, CADD 16.50, Variant assessed as somatic; moderate impact.
- G24* (p.Gly24Ter), gnomAD 16-23679002-G-T, CADD 34.00
- G24A (p.Gly24Ala), gnomAD 16-23679003-G-C, REVEL 0.13, CADD 14.70
- G24G (p.Gly24Gly), rs1443412261, gnomAD 16-23679004-A-G, CADD 4.88
- V25I (p.Val25Ile), ExAC rs749921244, TOPMed rs749921244, gnomAD rs749921244, REVEL 0.06, CADD 3.32
- p.Val25 Gly29del, gnomAD 16-23678998-CCCCG, CADD 17.80
- V25V (p.Val25Val), gnomAD 16-23679007-T-G, CADD 4.80
- A26T (p.Ala26Thr), ExAC rs758028407, TOPMed rs758028407, gnomAD rs758028407, REVEL 0.15, CADD 21.70, Uncertain significance, not specified
- A26V (p.Ala26Val), gnomAD 16-23679009-C-T, REVEL 0.17, CADD 20.40
- A26A (p.Ala26Ala), gnomAD 16-23679010-A-G, CADD 8.31
- A27P (p.Ala27Pro), ExAC rs780089094, TOPMed rs780089094, gnomAD rs780089094, REVEL 0.26, CADD 21.80
- A27V (p.Ala27Val), TOPMed rs1315465388, REVEL 0.12, CADD 9.50
- A27S (p.Ala27Ser), gnomAD 16-23679011-G-T, REVEL 0.14, CADD 18.60
- A27A (p.Ala27Ala), rs746949141, gnomAD 16-23679013-T-A, CADD 11.20
- P28A (p.Pro28Ala), ExAC rs754746085, TOPMed rs754746085, gnomAD rs754746085, REVEL 0.20, CADD 9.57, Uncertain significance, not specified
- P28L (p.Pro28Leu), ExAC rs748043179, TOPMed rs748043179, gnomAD rs748043179, REVEL 0.29, CADD 15.00
- P28S (p.Pro28Ser), rs754746085, ExAC rs754746085, TOPMed rs754746085, gnomAD rs754746085, REVEL 0.19, CADD 11.40, Variant assessed as somatic; moderate impact.
- P28T (p.Pro28Thr), gnomAD 16-23679014-C-A, REVEL 0.21, CADD 10.00
- P28P (p.Pro28Pro), gnomAD 16-23679016-C-T, CADD 5.52
- G29E (p.Gly29Glu), gnomAD 16-23679016-CG-C, CADD 25.00
- A30T (p.Ala30Thr), ExAC rs771030731, TOPMed rs771030731, gnomAD rs771030731, REVEL 0.07, CADD 14.90, Uncertain significance, not specified
- A30V (p.Ala30Val), gnomAD rs1380681511, REVEL 0.07, CADD 14.70
- A30G (p.Ala30Gly), gnomAD 16-23679012-CTCCC, CADD 32.00
- P31R (p.Pro31Arg), gnomAD 16-23679024-C-G, REVEL 0.21, CADD 15.10
- P31P (p.Pro31Pro), rs923151190, gnomAD 16-23679025-G-C, CADD 5.93
- A32V (p.Ala32Val), TOPMed rs933156352, gnomAD rs933156352, REVEL 0.14, CADD 15.60
- A32E (p.Ala32Glu), gnomAD 16-23679027-C-A, REVEL 0.14, CADD 13.80
- A33S (p.Ala33Ser), gnomAD rs1959279291, REVEL 0.04, CADD 12.90
- A33V (p.Ala33Val), ExAC rs774608785, TOPMed rs774608785, gnomAD rs774608785, REVEL 0.09, CADD 18.90
- A34T (p.Ala34Thr), gnomAD rs1338733957, REVEL 0.10, CADD 15.20
- A34L (p.Ala34Leu), gnomAD 16-23679022-TCCGG, CADD 32.00
- A34V (p.Ala34Val), gnomAD 16-23679033-C-T, REVEL 0.11, CADD 14.10
- A34A (p.Ala34Ala), rs1358684596, gnomAD 16-23679034-T-C, CADD 2.74
- P35L (p.Pro35Leu), TOPMed rs1212626444, gnomAD rs1212626444, REVEL 0.22, CADD 15.10
- P35S (p.Pro35Ser), gnomAD 16-23679035-C-T, REVEL 0.18, CADD 14.90
- P35R (p.Pro35Arg), gnomAD 16-23679036-C-G, REVEL 0.24, CADD 14.60
- P36L (p.Pro36Leu), rs983282909, ClinGen CA279535620, ClinVar RCV004326505, TOPMed rs983282909, REVEL 0.17, CADD 16.80, Uncertain significance, not specified
- P36T (p.Pro36Thr), ExAC rs745902058, TOPMed rs745902058, gnomAD rs745902058, REVEL 0.10, CADD 16.00
- P36Q (p.Pro36Gln), gnomAD 16-23679039-C-A, REVEL 0.15, CADD 16.20
- P36R (p.Pro36Arg), gnomAD 16-23679039-C-G, REVEL 0.14, CADD 16.10
- P36P (p.Pro36Pro), rs1449267402, gnomAD 16-23679040-G-A, CADD 7.54
- A37E (p.Ala37Glu), TOPMed rs1959280009, REVEL 0.16, CADD 15.40
- A37V (p.Ala37Val), TOPMed rs1959280009, REVEL 0.08, CADD 19.10
- A37A (p.Ala37Ala), gnomAD 16-23679043-G-C, CADD 11.40
- K38K (p.Lys38Lys), rs775905226, gnomAD 16-23679046-A-G, CADD 11.10
- E39D (p.Glu39Asp), Ensembl rs1260213034, REVEL 0.26, CADD 22.20
- E39R (p.Glu39Arg), gnomAD 16-23679043-GA-G, CADD 28.90
- I40T (p.Ile40Thr), gnomAD 16-23679051-T-C, REVEL 0.57, CADD 29.00
- I40I (p.Ile40Ile), rs761098057, gnomAD 16-23679052-C-T, CADD 13.30
- P41S (p.Pro41Ser), TOPMed rs1241134783, gnomAD rs1241134783, REVEL 0.46, CADD 27.00
- P41T (p.Pro41Thr), TOPMed rs1241134783, gnomAD rs1241134783, REVEL 0.54, CADD 26.60
- P41L (p.Pro41Leu), gnomAD 16-23679054-C-T, REVEL 0.55, CADD 29.00
- P41P (p.Pro41Pro), rs764715667, gnomAD 16-23679055-G-A, CADD 9.18
- E42K (p.Glu42Lys), TOPMed rs1959280716, REVEL 0.25, CADD 23.80
- E42Q (p.Glu42Gln), gnomAD 16-23679056-G-C, REVEL 0.19, CADD 23.40
- E42E (p.Glu42Glu), rs1187592252, gnomAD 16-23679058-G-A, CADD 14.40
- V43A (p.Val43Ala), rs1597133306, ClinGen CA395148816, ClinVar RCV001250902, Ensembl rs1597133306, AlphaMissense 0.38, MetaLR 0.47, Uncertain significance, Recurrent spontaneous abortion
- V43G (p.Val43Gly), Ensembl rs1597133306, Uncertain significance
- V43F (p.Val43Phe), gnomAD 16-23679059-G-T, REVEL 0.31, CADD 19.10
- V43V (p.Val43Val), gnomAD 16-23679061-C-G, CADD 14.70
- L44P (p.Leu44Pro), Ensembl rs1597133314
- L44L (p.Leu44Leu), gnomAD 16-23679062-C-T, CADD 14.20
- V45L (p.Val45Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V45A (p.Val45Ala), gnomAD 16-23679066-T-C, REVEL 0.18, CADD 23.10
- D46N (p.Asp46Asn), NCI-TCGA Cosmic COSV1002, Variant assessed as somatic; moderate impact.
- D46G (p.Asp46Gly), gnomAD 16-23679069-A-G, REVEL 0.77, CADD 32.00
- D46E (p.Asp46Glu), gnomAD 16-23679070-C-G, REVEL 0.47, CADD 24.20
- P47L (p.Pro47Leu), gnomAD rs1474208424
- P47S (p.Pro47Ser), TOPMed rs1369881552, gnomAD rs1369881552, REVEL 0.26, CADD 22.70
- P47P (p.Pro47Pro), rs776851865, gnomAD 16-23679073-A-G, CADD 14.10
- R48C (p.Arg48Cys), gnomAD rs1423348958, REVEL 0.65, CADD 32.00
- R48H (p.Arg48His), NCI-TCGA Cosmic COSV5562, Variant assessed as somatic; moderate impact.
- R48R (p.Arg48Arg), rs375647790, gnomAD 16-23679076-C-A, CADD 15.70
- S49R (p.Ser49Arg), gnomAD 16-23679076-C-CAG, CADD 29.60
- S49N (p.Ser49Asn), gnomAD 16-23679078-G-A, REVEL 0.25, CADD 22.30
- S49S (p.Ser49Ser), gnomAD 16-23679079-C-T, CADD 14.10
- R50G (p.Arg50Gly), ExAC rs764772076, TOPMed rs764772076, gnomAD rs764772076, REVEL 0.27, CADD 22.40
- R50L (p.Arg50Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R50Q (p.Arg50Gln), gnomAD rs1404475875
- R50W (p.Arg50Trp), gnomAD 16-23679080-C-T, REVEL 0.50, CADD 32.00
- R51W (p.Arg51Trp), gnomAD 16-23679083-C-T, REVEL 0.31, CADD 32.00
- R52H (p.Arg52His), ExAC rs750121456, TOPMed rs750121456, gnomAD rs750121456, REVEL 0.26, CADD 23.40
- R52R (p.Arg52Arg), rs1334879283, gnomAD 16-23679088-C-G, CADD 16.40
- p.Tyr53 Val54insIle, gnomAD 16-23679091-T-TAT, CADD 19.60
- R55W (p.Arg55Trp), Ensembl rs984792608, REVEL 0.67, CADD 32.00
- R55R (p.Arg55Arg), rs984792608, gnomAD 16-23679095-C-A, CADD 16.30
- G56S (p.Gly56Ser), gnomAD rs1342552399
- G56G (p.Gly56Gly), rs1292112671, gnomAD 16-23679100-C-A, CADD 11.30
- R57C (p.Arg57Cys), ExAC rs757915883, gnomAD rs757915883, REVEL 0.30, CADD 32.00
- R57S (p.Arg57Ser), rs757915883, NCI-TCGA Cosmic COSV5562, ExAC rs757915883, gnomAD rs757915883, REVEL 0.24, CADD 24.90, Variant assessed as somatic; moderate impact.
- R57H (p.Arg57His), gnomAD 16-23679102-G-A, REVEL 0.20, CADD 32.00
- L59W (p.Leu59Trp), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
Public PLK1 analysis runs
- PLK1 analysis run — PLK1 (776 variants) — completed 2026-08-20